Research programme: cannabis-based therapeutics - NEMUS Bioscience

Drug Profile

Research programme: cannabis-based therapeutics - NEMUS Bioscience

Alternative Names: Cannabidiol derivatives - NEMUS; Cannabionoid therapeutics - NEMUS; CBD derivatives - NEMUS; NB 1111; NB 1222; NB 2111; NB 2221; NB 2222; NB 23R1; NB 3111; NB 31R1; NB 51R1; NB3000 series; THC-valine-hemisuccinate; UM 5070

Latest Information Update: 25 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NEMUS Bioscience; University of Mississippi
  • Class Cannabinoids; Non-opioid analgesics
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced nausea and vomiting; Methicillin-resistant Staphylococcus aureus infections; Muscle spasticity; Open-angle glaucoma; Pain; Peripheral nervous system diseases
  • Research Anxiety disorders; Diabetic retinopathy; Dry eyes; Epilepsy; Macular degeneration; Uveitis

Most Recent Events

  • 25 Jun 2017 NEMUS Bioscience plans a clinical trial of NB 1111 for glaucoma (ophthalmic)
  • 09 May 2017 Nemus Bioscience has patent protection for ocular delivery of THC-valine-hemisuccinate and other cannabinoid-based molecules in USA
  • 23 Mar 2017 Research programme: cannabis-based therapeutics - NEMUS Bioscience is available for licensing as of 03 Mar 2017. http://www.nemusbioscience.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top